HOOK HOOKIPA Pharma Inc.

Overview and Growth

In fiscal 2024, HOOKIPA Pharma Inc. recorded $43.95M of revenue, net loss of $43.50M, and an operating cash outflow of $76.98M. The $43.95M revenue base provides substantial context for the company’s earnings, cash generation, and capital requirements. Revenue was 118.3% above fiscal 2023 revenue of $20.13M, marking a year-over-year increase. The company reported diluted EPS of -$3.47, adding a shareholder-level measure to the absolute income figures considered below. The diluted weighted-average share count was 12.54M, linking total earnings with the per-share result received by shareholders. Total assets stood at $82.55M, showing the scale of resources supporting revenue, earnings, liquidity, and financing. The revenue-to-assets relationship was 0.53x, showing the sales generated relative to the resources carried on the balance sheet.

Profitability

The company recorded an operating loss of $51.45M after the reported operating expense base. An operating margin of -117.1% reflected costs exceeding revenue-level gross profit by 117.1% of sales. The bottom-line result was a net loss of $43.50M after operating, financing, tax, and other recognized items. The net loss equaled 99.0% of revenue, showing the bottom-line deficit relative to the company’s sales base. The company reported negative EBITDA of $48.70M, adding a pre-interest, tax, depreciation, and amortization view of the operating shortfall. The pretax result was a loss of $43.61M, establishing the deficit before tax effects. Pretax margin was -99.2%, reflecting a pre-tax loss equal to 99.2% of revenue. An income-tax benefit of $106.00K improved the final result relative to pretax income or loss. The net loss equaled 84.9% of period-end equity, showing the deficit relative to book capital. The net loss equaled 52.7% of period-end assets, showing the deficit relative to the asset base. The net loss narrowed to $43.50M from $81.58M in fiscal 2023.

Liquidity and Capital Structure

At period end, the $82.55M asset base was financed through $31.33M of liabilities and $51.21M of equity. The near-term balance sheet paired $80.67M of current assets with $24.65M of current liabilities at the reporting date. The current ratio was 3.27x, with current assets exceeding current liabilities and providing a short-term liquidity cushion. The company held $39.68M in cash and equivalents, a narrower liquidity measure than total current assets. Cash and equivalents represented 161.0% of current liabilities, showing the portion of near-term obligations matched by reported cash alone. Equity equaled 62.0% of assets, showing the shareholder-capital layer within the company’s balance sheet. The liabilities-to-assets relationship was 38.0%, placing reported obligations against the full positive asset balance. Cash and equivalents equaled 48.1% of total assets, showing the liquid cash component within the company’s broader resource base. Total assets were 48.8% lower than fiscal 2023 assets of $161.34M, measuring the company’s own balance-sheet change. Reported equity changed 43.0% from $89.86M in fiscal 2023, placing the current capital base lower year over year. Compared with $117.10M in fiscal 2023, the current cash balance moved 66.1% and finished lower.

Cash Flow and Earnings Quality

Operating activities used $76.98M of cash, resulting in an operating cash outflow for the year. The company spent $194.00K on capital expenditures while operations also absorbed cash, so both ongoing activity and investment drew on liquidity during the period. Negative free cash flow was $77.17M, leaving a cash deficit after capital spending and reducing financial flexibility. Free-cash-flow margin was -175.6%, reflecting a cash deficit equal to 175.6% of revenue after capital spending. The cash deficit after capital spending represented 93.5% of the period-end asset base. The operating cash outflow widened to $76.98M from $57.52M in fiscal 2023.

Based on the annual report for the fiscal year ending Dec 31, 2024. Analysis generated Sep 24, 2026.